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Down syndrome is a genetic condition characterised by the presence 
of all or part of an extra chromosome 21 and is linked to a spectrum 
of medical and phenotypic features.[1-3] Chromosome 21 is associated 
with tumour suppressor gene expression, and the presence of the extra 
chromosome allows for some favourable effects, making it one of the 
most powerful natural protection agents against many solid tumours 
such as breast cancer in women.[3] On the other hand, individuals 
with trisomy 21 tend to have societal and hormonal risk factors for 
breast cancer, including frequent nulliparity, lack of breastfeeding, 
physical inactivity and high body mass index,[4] and unfortunately 
they are also prone to blood cancers such as leukaemia.[5]
The life expectancy of individuals living with Down syndrome 
has increased markedly from 25 to 60 years in the past 30 years.[6] 
With that came questions as to whether screening policies for breast 
cancer should also apply to people with Down syndrome as compared 
with the general population. In particular screening policies such as 
mammography have been looked at. It was found that it did not serve 
much of a clinical benefit and to be financially costly. The cost per 
finding was high, hence the benefit of mammograms is questionable, 
and the potential for harm appears to be greater as studies have 
demonstrated that <1% of the women with Down syndrome develop 
breast cancer.[6-9]
Dey et al.[2] reported the first case of triple negative breast cancer, 
and we report a similar case in a 26-year old woman with breast 
cancer in Down syndrome subtype luminal A. We are hoping to bring 
further insights into this rare condition and spark research that will 
assist in gaining more insights into this condition. Ethical approval 
was obtained from Pietersburg/Mankweng Hospital Research Ethics 
Committee (ref. no. PMREC 26 MAY UL 2021/B).
Case 
A 26-year-old female patient presented at Mankweng Hospital breast 
oncology clinic as a referral from a peripheral hospital. She was born 
in a rural township as one of six siblings. At a young age, her mother 
noticed that her development was grossly delayed compared with the 
other children. She was born with Down syndrome and was noted 
to have hypothyroidism. No other associated congenital defects were 
detected at birth. She was solely cared for by her family and was never 
able to go to school due to need for special schooling and the family’s 
financial constraints.
This young lady and her mom started noticing a lump in her left 
breast, which had been progressively growing over the past 2 years. 
It was not painful, had no associated skin changes or nipple discharge, 
and no axillary masses were noted. Menarche was reported to have 
been at 15 years of age, she experienced regular menstrual periods, 
was not on contraception and has never been pregnant.
Although she was noted to have low thyroid levels at birth, she was 
not on treatment and was clinically euthyroid. She had no previous 
operations and no comorbid conditions of note. The patient had 
completed neo-adjuvant therapy within a week of presenting to 
the clinic. Prior to chemotherapy, she was assessed as stage 4 breast 
cancer, with a tumour size of 7 cm in its greatest diameter in the left 
upper outer breast quadrant. There was no skin or chest involvement, 
but there was ipsilateral axillary lymph node involvement and 
metastasis to the thoraco-lumbar spine detected on bone scan. 
Family history as well as social history was non-contributory. Upon 
examination, she was found to be of short stature and had physical 
features in keeping with Down syndrome. Vitals were stable, with 
blood pressure at 100/67 mmHg and pulse at 75 beats per minute. 
She was apyrexial and weighed 65.5 kg. Breast examination showed 
asymmetrical breasts with left breast showing a bulge over the upper 
outer quadrant. No skin changes, and no palpable axillary lymph 
nodes. There was a palpable mass on the outer upper quadrant that 
was 5 cm in its widest diameter. It was not attached to the skin of the 
chest wall. The cancer was clinically stage 4, with bone metastasis 
to the 9th and 5th lumbar vertebrae. The rest of the. The rest of the 
systematic examination was unremarkable. Histology results from a 
core biopsy confirmed an infiltrating ductal subtype/carcinoma of no 
special type. Modified Nottingham-Bloom-Richardson grading score 
was a total score of 7 (tubules = 3, pleomorphism = 3, mitoses = 1), 
making it a grade 2 or moderately differentiated adenocarcinoma. 
Immunohistochemistry revealed that the cells were oestrogen 
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receptor positive, progesterone receptor positive, c-erbB positive and 
8% of the cells were Ki-67 positive, making it a luminal B (HER2-
positive) molecular subtype. Mammogram findings were breast 
imaging – reporting and data system (BI-RADS) 5, which was highly 
suggestive of malignancy on the left breast. Bone scan revealed bone 
metastasis localised to the 9th thoracic and 5th lumbar vertebrae. 
Tumour marker (CA 15-3) was 7. The patient had a good clinical 
response to chemotherapy and a simple mastectomy was done.
Discussion
This case is similar to the previously described case of triple negative 
breast cancer in Down syndrome.[2] However, to the best of our 
knowledge, it is a first of its kind to be described as an advanced stage 
4 luminal B (HER2+) breast cancer in an African female. Among the 
many genes expressed in chromosome 21, of particular importance 
is runx1. Runt-related transcription factor 1 (RUNX1), also known 
as acute myeloid leukaemia 1 (AML1) protein or core-binding factor 
subunit alpha-2 (CBFA2), is a protein that is encoded by the runx1 
gene in humans.[10] RUNX1 plays a critical role in the early stages 
of haematopoiesis, is often expressed in breast epithelium, and is 
deregulated during tumorigenesis. It has been noted that runx1 
functions as both an oncogene and tumour suppressor gene in 
breast cancer, acting as a tumour suppressor in oestrogen receptor-
positive tumours and an oncogene in oestrogen receptor-negative 
tumours.[10] Understanding the role of RUNX1 does provide some 
insight into why individuals with Down syndrome have a higher risk 
of leukaemia and a reduced case frequency of breast cancer. More 
studies are needed to further clarify this, and hopefully in future 
we will be able to propose screening techniques for individuals 
living with Down syndrome who may have an increased risk of 
also developing breast cancer rather than using the same screening 
techniques used for screening non-Down syndrome patients, which 
has been shown to be of no clinical benefit and is costly.[8]
The patient in the case study had breast cancer, which was 
classified with the use of immunohistochemistry as luminal B 
(oestrogen receptor-positive, progesterone receptor-positive, 
HER2+ and Ki 67 of 8%) molecular subtype. Based on a study 
conducted at Third Hospital of Nanchang City[11] over the period 
2005 - 2015, luminal B was found to the commonest subtype, 
and the majority of the affected individuals were below the age of 
50  years (p=0.018). Furthermore, luminal B has been associated 
with unfavourable clinical outcomes such as poorer disease-free 
survival, increased risk of early relapse, appears to be limited to the 
early period after surgery and within the first 5 years after diagnosis, 
predisposition to  relapse in bone and pleura similar to luminal A, 
with bone metastasis more common than lung, relative insensitivity 
to endocrine therapy compared with luminal A subtype and relative 
insensitivity to chemotherapy compared with basal-like and HER2-
positive subtypes.[12-14] With such poor clinical outcomes, the need 
for early detection, diagnosis and individualised treatment strategies 
remains of crucial importance, more so for individuals living with 
Down syndrome, as other than having intellectual disability, social 
and financial constraints, they suffer from other medical conditions 
that can alter adherence to treatment and follow-up as luminal-B 
breast cancer has been shown to have poor response to hormonal 
and chemotherapy. [13] Management stills remains a challenge for 
individuals with luminal-B breast cancer.
Conclusion
Luminal-B subtype remains a clinically important classification of 
breast cancer with prognostic and potential predictive implications. 
Due to the nature of the impairments in individuals with Down 
syndrome, such as intellectual disability, it may be difficult for 
early recognition of many conditions, breast cancer included, and 
hence poses an early detection and diagnostic challenge. For these 
reasons, an understanding of the relationship between breast cancer, 
molecular subtypes and Down syndrome is vital for researchers 
and clinicians, and for the education of individuals living with 
Down syndrome and their families, more so for the formulation of 
individualised treatment strategies. More research is encouraged 
to further guide our understanding and aid in the formulation of 
management protocols relevant to this population.
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